Literature DB >> 22865582

Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.

Anna Fialová1, Simona Partlová, Luděk Sojka, Hana Hromádková, Tomáš Brtnický, Jitka Fučíková, Petr Kocián, Lukáš Rob, Jiřina Bartůňková, Radek Spíšek.   

Abstract

The type of immune cells that are present within the tumor microenvironment can play a crucial role in the survival of patients. However, little is known about the dynamics of the tumor-infiltrating immune cells during disease progression. We studied the immune cells that infiltrated the tumor tissues of ovarian cancer patients at different stages of disease. The early stages of development of ovarian carcinomas were characterized by a strong Th17 immune response, whereas in stage II patients, recruitment of high numbers of Th1 cells was observed. In disseminated tumors (Stages III-IV), we detected a dominant population of Helios(+) activated regulatory T cells (Tregs) along with high numbers of monocytes/macrophages and myeloid dendritic cells (mDCs). Tumor-infiltrating Tregs had markedly lower expression of CCR4 than circulating Tregs, and the numbers of tumor-infiltrating Tregs significantly correlated with the levels of CCL22 in ovarian tumor cell culture supernatants, suggesting their recruitment via a CCR4/CCL22 interaction. CCL22 was mainly produced by tumor cells, monocytes/macrophages and mDCs in the primary ovarian tumors, and its expression markedly increased in response to IFNγ. Taken together, the specific recruitment of Tregs, probably triggered by inflammatory stimuli, leads to a significant immune suppression in the advanced stages of ovarian cancer.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865582     DOI: 10.1002/ijc.27759

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.

Authors:  A Jafarzadeh; H Fooladseresht; K Minaee; M R Bazrafshani; A Khosravimashizi; M Nemati; M Mohammadizadeh; M M Mohammadi; A Ghaderi
Journal:  Tumour Biol       Date:  2014-10-22

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

3.  Host CYP27A1 expression is essential for ovarian cancer progression.

Authors:  Sisi He; Liqian Ma; Amy E Baek; Anna Vardanyan; Varsha Vembar; Joy J Chen; Adam T Nelson; Joanna E Burdette; Erik R Nelson
Journal:  Endocr Relat Cancer       Date:  2019-07       Impact factor: 5.678

Review 4.  Advances in distinguishing natural from induced Foxp3(+) regulatory T cells.

Authors:  Xiaohong Lin; Maogen Chen; Ya Liu; Zhiyong Guo; Xiaoshun He; David Brand; Song Guo Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

5.  [Th1/Th2 and Treg/Th17 cell balance in peripheral blood of patients with ovarian cancer].

Authors:  Li-Hua Wang; Liang-Liang Wang; Jing Zhang; Pei Zhang; Sheng-Ze Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

6.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

7.  Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.

Authors:  E C Halvorsen; M J Hamilton; A Young; B J Wadsworth; N E LePard; H N Lee; N Firmino; J L Collier; K L Bennewith
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

8.  Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Authors:  Dhifaf Sarhan; Keli L Hippen; Amanda Lemire; Skyler Hying; Xianghua Luo; Todd Lenvik; Julie Curtsinger; Zachary Davis; Bin Zhang; Sarah Cooley; Frank Cichocki; Bruce R Blazar; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2018-05-21       Impact factor: 11.151

9.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Polymer-loaded hydrogels serve as depots for lactate and mimic "cold" tumor microenvironments.

Authors:  Riley Allen; Emilie Ivtchenko; Bhasirie Thuamsang; Rapeepat Sangsuwan; Jamal S Lewis
Journal:  Biomater Sci       Date:  2020-10-01       Impact factor: 6.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.